Table 2.
Major clinical and therapeutic characteristics in CPs according to SARS-CoV-2 infection after vaccination.
| All Cancer Patients (↨) |
CPs with Infection after Vaccination (⇥) |
CPs without Infection after Vaccination (⇥) |
p Value | ||
|---|---|---|---|---|---|
| Total, n | 840 | 49 (5.8%) | 791 (94.2%) | ||
| Age in years, mean (SD) | 61.3 (12.2) | 55.2 (12.8) | 61.7 (12.1) | 0.001 | |
| Sex, n (%) | Women | 573 (68.2%) | 40 (7%) | 533 (93%) | 0.055 |
| Men | 267 (31.8%) | 9 (3.4%) | 258 (96.6%) | - | |
| BMI, n (%) | <18 kg/m2 | 16 (2.1%) | 2 (12.5%) | 14 (87.5%) | 0.405 |
| 18–24.9 kg/m2 | 357 (46.1%) | 17 (4.8%) | 340 (95.2%) | - | |
| 25–30 kg/m2 | 258 (33.3%) | 16 (6.2%) | 242 (93.8%) | - | |
| >30 kg/m2 | 144 (18.6%) | 7 (4.9%) | 137 (95.1%) | - | |
| missing | 65 | 7 | 58 | ||
| Diabetes mellitus, n (%) | No | 578 (89.3%) | 40 (6.9%) | 538 (93.1%) | 0.299 |
| Yes | 69 (10.7%) | 2 (2.9%) | 67 (97.1%) | - | |
| missing | 193 | 7 | 186 | ||
| Primitive tumor, n (%) | gastrointestinal cancer | 29 (3.5%) | 3 (10.3%) | 26 (89.7%) | 0.133 |
| gynecologic and breast cancer | 479 (57%) | 33 (6.9%) | 446 (93.1%) | - | |
| urologic cancer | 123 (14.6%) | 3 (2.4%) | 120 (97.6%) | - | |
| other location cancer | 209 (24.9%) | 10 (4.8%) | 199 (95.2%) | - | |
| Cancer stage, n (%) | localized stage | 244 (29%) | 21 (8.6%) | 223 (91.4%) | 0.064 |
| locally advanced stage | 168 (20%) | 10 (6%) | 158 (94%) | - | |
| metastatic stage | 428 (51%) | 18 (4.2%) | 410 (95.8%) | - | |
| Self-reported SARS-CoV-2 infection before the first vaccine injection, n (%) |
none | 793 (94.4%) | 45 (5.7%) | 748 (94.3%) | 0.346 |
| at least one infection | 47 (5.6%) | 4 (8.5%) | 43 (91.5%) | - | |
| Chemotherapy, n (%) ¥ | not received | 234 (27.9%) | 19 (8.1%) | 215 (91.9%) | 0.09 |
| ongoing treatment | 209 (24.9%) | 14 (6.7%) | 195 (93.3%) | - | |
| received and finished | 396 (47.2%) | 16 (4%) | 380 (96%) | - | |
| Radiotherapy, n (%) | not received | 479 (57%) | 39 (8.1%) | 440 (91.9%) | 0.004 |
| ongoing treatment | 24 (2.9%) | 0 (0%) | 24 (100%) | - | |
| received and finished | 337 (40.1%) | 10 (3%) | 327 (97%) | - | |
| Hormonotherapy, n (%) § | not received | 634 (75.8%) | 46 (7.3%) | 588 (92.7%) | 0.008 |
| ongoing treatment | 137 (16.4%) | 1 (0.7%) | 136 (99.3%) | - | |
| received and finished | 65 (7.8%) | 2 (3.1%) | 63 (96.9%) | - | |
| Immunotherapy, n (%) ¥ | not received | 541 (64.5%) | 41 (7.6%) | 500 (92.4%) | 0.014 |
| ongoing treatment | 247 (29.4%) | 6 (2.4%) | 241 (97.6%) | - | |
| received and finished | 51 (6.1%) | 2 (3.9%) | 49 (96.1%) | - | |
| Targeted therapy, n (%) | not received | 536 (63.8%) | 37 (6.9%) | 499 (93.1%) | 0.137 |
| ongoing treatment | 208 (24.8%) | 10 (4.8%) | 198 (95.2%) | - | |
| received and finished | 96 (11.4%) | 2 (2.1%) | 94 (97.9%) | - | |
| Surgery, n (%) | no cancer surgery | 353 (42%) | 29 (8.2%) | 324 (91.8%) | 0.018 |
| surgery before vaccination: | 487 (58%) | 20 (4.1%) | 467 (95.9%) | - | |
| <1 year | 193/487 (39.6%) | 9 (4.7%) | 184 (95.3%) | 0.789 | |
| ≥1 year | 294/487 (60.4%) | 11 (3.7%) | 283 (96.3%) | - | |
| <3 months | 26/487 (5.3%) | 3/26 (11.5%) | 23/26 (88.5%) | 0.146 | |
| >3 months | 461/487 (94.7%) | 17/461 (3.7%) | 444/461 (96.3%) | - |
CP: cancer patient; SD: standard deviation; BMI: body mass index. Proportions are presented as column percentage (↨) for the whole CP cohort and as row percentage (⇥) for subgroup values. ¥ 1 CP had missing information for the end date of this treatment; § 4 CPs had missing information for the end date of this treatment.